The Technical Analyst
Organovo Holdings Inc [ONVO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Organovo Holdings Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.25% $0.991
America/New_York / 26 apr 2024 @ 11:51
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.95 mill |
| EPS: | -2.16 |
| P/E: | -0.460 |
| Earnings Date: | Jul 11, 2024 |
| SharesOutstanding: | 10.04 mill |
| Avg Daily Volume: | 1.024 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.460 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.08x |
| Company: PE -0.460 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.508 (52.24%) $0.518 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.934 - 1.048 ( +/- 5.75%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-17 | Stern Adam K | Buy | 19 607 | Common Stock |
| 2023-11-17 | Milhous Alison Tjosvold | Buy | 19 607 | Common Stock |
| 2023-11-17 | Cohen Douglas Jay | Buy | 19 607 | Common Stock |
| 2023-11-17 | Murphy Keith | Buy | 19 607 | Common Stock |
| 2023-11-17 | Gobel David | Buy | 19 607 | Common Stock |
| INSIDER POWER |
|---|
| 81.41 |
| Last 90 transactions |
| Buy: 3 116 580 | Sell: 414 691 |
Forecast:
13:30 - $1.003
Live Trading Signals (every 1 min)
Forecast
1: 12:00 - $0.996
Forecast 2: 12:50 - $1.003
Forecast 3: 13:30 - $1.003
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.991 (0.25% ) |
| Volume | 0.0464 mill |
| Avg. Vol. | 1.024 mill |
| % of Avg. Vol | 4.53 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ONVO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ONVO
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Latest Press Releases
2024-04-15 08:05:00 - Press Release
Organovo Announces Positive Phase 2 Results For Fxr314 In Metabolic Dysfunction-associated Steatohepatitis (mash) Showing Both Reduction In Liver Fat Content And Strong Safety And Tolerability Compared To Placebo
Organovo announces positive phase 2 results for fxr314 in metabolic dysfunction-associated steatohepatitis (mash) showing both reduction in liver fat conte
2024-01-25 08:05:00 - Press Release
Organovo Presents Fxr314 3d Human Tissue Model Findings That Show Improved Epithelial Barrier Function And Fibrosis Reduction At Crohn's And Colitis Congress
San diego, jan. 25, 2024 (globe newswire) -- organovo holdings, inc. (nasdaq: onvo), a clinical stage biotechnology company focused on developing fxr314 in inflammatory bowel disease (ibd), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3d) human tissues, today announced the presentation of preclinical data related to the company's fxr314 development program in its proprietary 3d human tissue models of crohn's disease and ulcerative colitis at the crohn's and colitis congress being held january 25-27, 2024 in las vegas, nevada.
2024-01-09 08:05:00 - Press Release
Organovo To Present Fxr314 Ibd 3d Model Findings At Upcoming Crohn's And Colitis Congress
San diego, jan. 09, 2024 (globe newswire) -- organovo holdings, inc. (nasdaq: onvo), a clinical stage biotechnology company that is focused on developing fxr314 in inflammatory bowel disease (ibd), including ulcerative colitis (uc), based on demonstration of clinical promise in three-dimensional (3d) human tissues as well as strong preclinical data, today announced that its data on the activity of fxr314 in its proprietary 3d human tissue models of crohn's disease and ulcerative colitis will be presented at the crohn's and colitis congress to be held january 25-27, 2024 in las vegas, nevada.
2023-12-06 08:05:00 - Press Release
Organovo Provides Timing For Release Of Fxr314 Phase 2 Nash Results
San diego, dec. 06, 2023 (globe newswire) -- organovo holdings, inc. (nasdaq: onvo), a clinical stage biotechnology company that is focused on developing fxr314 in ulcerative colitis and inflammatory bowel disease (ibd), based on demonstration of clinical promise in three-dimensional (3d) human tissues as well as strong preclinical data, today announced that it will release final and complete data from a phase 2a trial of fxr314 in non-alcoholic steatohepatitis (nash) patients by april 2024. the company anticipates presentations at scientific meetings as well as publication in peer-reviewed journals. the release of this data will be the first public release of the completed clinical trial data.
2023-11-13 08:05:00 - Press Release
Correction – Organovo Highlights Fxr314 Combination Therapy Potential And Plan
San diego, nov. 13, 2023 (globe newswire) -- in a release issued under the same headline on november 8, 2023 by organovo, inc. (nasdaq: onvo), a link was incorrect. the corrected release follows:
Latest News
2024-04-15 08:28:33 - Reuters
Organovo's fatty liver disease drug meets main goal in mid-stage study
Organovo Holdings said on Monday its experimental drug to treat a type of fatty liver disease met the main goal in a mid-stage study, sending its shares up nearly 27% in premarket trade.
2024-01-09 08:05:00 - GlobeNewsWire
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn's disease and ulcerative colitis will be presented at the Crohn's and Colitis Congress to be held January 25-27, 2024 in Las Vegas, Nevada.
2023-09-08 12:46:00 - GlobeNewsWire
Organovo to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
2022-09-06 08:20:00 - GlobeNewsWire
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Executive Chairman, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022.
2022-03-03 22:13:39 - The Motley Fool
Why Organovo Holdings, Inc. Stock Soared 49.7% This Week
The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.
2021-09-17 16:10:00 - GlobeNewsWire
Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
SOLANA BEACH, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that the Company's annual meeting of shareholders, on September 14, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum.
2021-05-28 09:54:57 - Seeking Alpha
Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside
Organovo Holdings, Inc. is an early-stage biotechnology company developing and utilizing highly customized 3D human tissues as dynamic models of health and diseased human biology for internal drug development. Organovo is transitioning its short-term offering from a heavily service-based business in 2019 to drug candidate development, projecting multiple INDs by 2025.
2021-03-11 15:58:29 - GuruFocus
Catherine Wood's ARK Investment Slashes Organovo Holding
Catherine Wood ( Trades , Portfolio )'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (NASDAQ:ONVO) position alongside a small reduction in the Syros Pharmaceuticals Inc. (NASDAQ:SYRS) position according to GuruFocus' Real-Time Picks, a Premium feature.
2021-03-02 08:05:00 - GlobeNewsWire
Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)
SOLANA BEACH, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences Conference. The conference is being held on March 9-10, 2021 virtually.
2021-01-19 13:56:04 - Seeking Alpha
ARKG: Potential Disruption For Healthcare And Pharma Industries
